Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma

por Apostolidis, John, Sayyed, Ayman, Darweesh, Mohammed, Kaloyannidis, Panayotis, Al Hashmi, Hani
Publicado 2020

Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach

por Kaloyannidis, Panayotis, Al Shaibani, Eshrak, Moinnudin, Asif, Al Anezi, Khalid, Al Hashmi, Hani
Publicado 2021

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease

por Kaloyannidis, Panayotis, Shaibani, Eshrak Al, Apostolidis, Ioannis, Kanfar, Solaf, Anezi, Khalid Al, Hashmi, Hani Al
Publicado 2018

ANTIBODY RESPONSES AND SAFETY OF THE COMMERCIALLY AVAILABLE VACCINES AGAINST SARS-COV-2 VIRUS IN ALLOGRAFTED PATIENTS: REAL WORLD DATA FROM A SINGLE CENTER

por Kaloyannidis, Panayotis, Blowi, Belal, Yahya, Rana, Khaldi, Hamdah Al, Attas, Rabab, Dayel, Afra, Kanfar, Solaf
Publicado 2022

Risk Assessment for Newly Diagnosed Fit Young Patients with Multiple Myeloma in the Era of Novel Treatment Modalities: Should There Be Additional Factors Taken into Consideration??

por Kaloyannidis, Panayotis, Abdulla, Fatema, Mutahar, Enas, Al Hashim, Haidar, Al Harbi, Salman, Estanislao, Analie, Al Hashmi, Hani
Publicado 2022

De Novo Psoriasis Vulgaris Diagnosed after Nivolumab Treatment for Refractory Hodgkin's Lymphoma, Completely Resolved after Autologous Hematopoietic Stem Cell Transplantation

por Kaloyannidis, Panayotis, Al Shaibani, Eshrak, Mashhour, Miral, Gamil, Mohammed, Apostolidis, Ioannis, Al Hashmi, Hani, Al Anazi, Khalid Ahmed
Publicado 2018

Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation

por Kaloyannidis, Panayotis, Hertzberg, Mark, Webb, Kate, Zomas, Athanasios, Schrover, Rudolf, Hurst, Michael, Jacob, Ian, Nikoglou, Thalia, Connors, Joseph M.
Publicado 2019

Single-Agent High-Dose Melphalan as Conditioning Regimen in Autologous Hematopoietic Stem Cell Transplantation for Hodgkin's Lymphoma: Safety, and Long-Term Efficacy

por Al Hashmi, Hani, Kaloyannidis, Panayotis, Kafnar, Solaf, Al Harbi, Salman, Shaibani, Eshrak, Mokhtar, Nihad, Abdulbaki, Manar, Al Darweesh, Mohammed, Bacal, Jenifer, Apostolidis, John, Anezi, Khalid Al
Publicado 2018

Establishing hematopoietic stem cell transplant programs; overcoming cost through collaboration

por Al-Hashmi, Hani, Alsagheir, Ahmed, Estanislao, Analie, Bacal, Jenifer, Alsuhebah, Ashraf, Alblowe, Belal, Raslan, Heba, Alsaber, Arwa, Albahrani, Ahmed, Almulhem, Norah, Alamri, Amal, Alsaleh, Khalid, Albeihany, Amal, Alabdulwahab, Amal, Bakkar, Mohammed, Kaloyannidis, Panayotis
Publicado 2020

Establishment of the First Comprehensive Adult and Pediatric Hematopoietic Stem Cell Transplant Unit in the United Arab Emirates: Rising to the Challenge

por Al-Shamsi, Humaid O., Abyad, Amin, Kaloyannidis, Panayotis, El-Saddik, Amro, Alrustamani, Ahmad, Abu Gheida, Ibrahim, Ziade, Azzam, Dreier, Norbert W., Ul-Haq, Urfan, Joshua, Thanda Lucy Ann, El Kinge, Abdul Rahman, Coelho, Ritika, Ibrahim, Dima, Afrit, Mehdi, Al-Lababidi, Bilal, Aabideen, Zainul, Sabhani, Mayur, Shah, Rakeshkumar, Makhlouf, Ghaith, Iskandaerani, Lana, Iqbal, Faryal, Narayanan, Shiny, Ameen, Mohammed, Morrison, Theresa, Khalil, Charbel, Mheidly, Kayane
Publicado 2022

Clinical course and outcomes of COVID‐19 in hematopoietic cell transplant patients, a regional report from the Middle East

por El Fakih, Riad, Haroon, Alfadil, Alfraih, Feras, Al-Khabori, Murtadha K., Alzahrani, Mohsen, Alhuraiji, Ahmad, Hamadah, Abdulaziz, AlJohani, Naif I., Alahmari, Bader, Essa, Mohammed F., Motabi, Ibraheem H., Tailor, Imran K., Almaghrabi, Reem S., Al-Farsi, Khalil, Abosoudah, Ibraheem, Ayas, Mouhab, Elhassan, Tusneem A., Suhebeh, Ashraf M., Ahmed, Syed Osman, Alhayli, Saud, Kaloyannidis, Panayotis, Alsaeed, Ahmad, Anezi, Khalid Al, Alamoudi, Sameer, Damlaj, Moussab, Hashmi, Hani Al, Aljurf, Mahmoud
Publicado 2021